Stéphanie Forté (@stephanie_forte) 's Twitter Profile
Stéphanie Forté

@stephanie_forte

ID: 993424477525442561

calendar_today07-05-2018 09:37:07

22 Tweet

83 Followers

322 Following

Maxime Tremblay-Gravel (@3rdheartsound) 's Twitter Profile Photo

Do ❤️ RCTs reflect actual population demographics? In our analysis, based on current trends, age and gender-representative enrollment for #HF would require decades! #aging #womenshearthealth ICMtl CHUM Quoc Nguyen x.com/circoutcomes/s…

Kevin Kuo (@captainav) 's Twitter Profile Photo

Congratulations Stéphanie Forté Stéphanie Forté and Nafanta Fadiga on your excellent work in showing a dramatic reduction in catheter related #thrombosis with thromboprophylaxis in #sicklecell patients at #ASH18 ash.confex.com/ash/2018/webpr…

Congratulations Stéphanie Forté <a href="/stephanie_forte/">Stéphanie Forté</a> and Nafanta Fadiga on your excellent work in showing a dramatic reduction in catheter related #thrombosis with thromboprophylaxis in #sicklecell patients at #ASH18 ash.confex.com/ash/2018/webpr…
Kevin Kuo (@captainav) 's Twitter Profile Photo

L-Arg compared to placebo reduces mean total analgesic medication score (MQS) (73 [95%CI: 62-84] vs. 120 [97-143]; p<0.001) in Oral L-Arg Therapy As a Novel Adjuvant in the Management of Acute Pain in #SickleCell Anemia Children in Nigeria: A RCT. by: Onalo R, et al. #ASH19

L-Arg compared to placebo reduces mean total analgesic medication score (MQS) (73 [95%CI: 62-84] vs. 120 [97-143]; p&lt;0.001) in Oral L-Arg Therapy As a Novel Adjuvant in the Management of Acute Pain in #SickleCell Anemia Children in Nigeria: A RCT. by: Onalo R, et al. #ASH19
Kevin Kuo (@captainav) 's Twitter Profile Photo

It is essential to publish negative trials! It promotes transparency and honesty. Inpatient infusion of Sevuparin 18 mg/kg/day had no effect on time to VOC resolution (ITT Cox prop. HR 0.89 (95%CI 0.61–1.30; p=0.554), in the TVOC01 trial by Biemond BJ, et al. #ASH19

It is essential to publish negative trials! It promotes transparency and honesty. Inpatient infusion of Sevuparin 18 mg/kg/day had no effect on time to VOC resolution (ITT Cox prop. HR 0.89 (95%CI 0.61–1.30; p=0.554), in the TVOC01 trial by Biemond BJ, et al. #ASH19
Kevin Kuo (@captainav) 's Twitter Profile Photo

This is the 2nd (3rd?) negative inpatient VOC trial: the first is GMI1070 (rivipansel), a pan-selectin inhibitor, the second is sevuparin, a heparinoid (Dr. Biemond mentioned Qari too). Is it because the horse (VOC) is out of the barn? Or the anti-adhesion road is a dead path?

Kevin Kuo (@captainav) 's Twitter Profile Photo

We are at risk of sounding like lymphoma docs with all the mAbs! Canakinumab (IL-1β blocker) reduced daily pain, fatigue, sleep and school absence. Double-Blind, Randomized Study of Canakinumab in Pediatric and AYA Patients with #SickleCell Anemia. by Rees DC, et al. #ASH19

Quoc Nguyen (@quocdngu) 's Twitter Profile Photo

Quelle tristesse, 53 décès annoncés. Entre la signature de l'armistice de 1918 et l'arrêt des combats, il y a eu 11 000 morts. Combien en aura-t-on entre aujourd'hui et le déploiement des vaccins chez les personnes âgées?

Madeleine Verhovsek, MD FRCPC (@mverhovsek) 's Twitter Profile Photo

Elegant study led by Stéphanie Forté that I was proud to be a part of! Hb C is a common carrier state in many areas. Thanks to work from the HRLMP molecular hematology lab, we can now say with certainty that it causes low MCV in most carriers, even if normal alpha global genes.

JAMA Network Open (@jamanetworkopen) 's Twitter Profile Photo

Early-onset dementia in sickle cell disease may be more common than we think. Screening of 252 adults using the RUDAS 6-minute questionnaire revealed a 10% prevalence of suspected dementia among those <60 years-old Stéphanie Forté Kevin Kuo ja.ma/2Qej3L8

Kevin Kuo (@captainav) 's Twitter Profile Photo

Identification of suspected dementia in a large proportion of #SickleCell patients with tools such as #RUDAS paves the way to diagnosis and rehabilitation. Thank you Stéphanie Forté and @DSoulieresMD CHUM for a successful collaboration!

Quoc Nguyen (@quocdngu) 's Twitter Profile Photo

Maintenant qu'Omicron est présent à Montréal, chaque plage où un vaccinateur est assis à attendre est une occasion perdue. S'il faut réduire à 5 mois pour les 70+ ou ouvrir pour les 60+ pour rectifier la situation, allons-y. Pas le temps de niaiser.

Dr. Robert Rohde (@rarohde) 's Twitter Profile Photo

To all the exasperated doctors and epidemiologists who saw this winter's COVID wave coming and wish that more had been done to prepare, We understand how you feel. Signed, All the climate scientists

Ziad Solh (@ziadsolh) 's Twitter Profile Photo

The adult equivalent of "The dog ate my homework" is "The kids took my laptop" . #WorkFromHome #WFH #missmyoffice #COVID22

Pat McGann, MD (@ptmcgann) 's Twitter Profile Photo

When you assess #SickleCell pain, the only number that matters is the patient’s pain rating. Not the heart rate, not the blood pressure, not the respiratory rate. Not the hemoglobin, fetal hemoglobin, or reticulocyte count. #BelievethePatient Listen, and treat the pain.

Kevin Kuo (@captainav) 's Twitter Profile Photo

#Sicklecell patients with central venous catheter but not on thromboprophylaxis had higher #VTE rates (rate ratio=4.0, p=0.02), and those on #hydroxyurea had lower #VTE rates (p<0.001) Forte S Stéphanie Forté, et al. JClinMed. 2022; 11(5):1193 mdpi.com/1512834

Kevin Kuo (@captainav) 's Twitter Profile Photo

Idowu M, et al. presented the primary analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism. 61% reduction in priapic events by week 26! The waterfall plot says it all. #ASH23

Idowu M, et al. presented the primary analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism. 61% reduction in priapic events by week 26!
The waterfall plot says it all.
#ASH23